La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
BioNTech Bilan de santé
Santé financière contrôle des critères 6/6
BioNTech possède un total de capitaux propres de €19.1B et une dette totale de €0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont €22.2B et de €3.2B.
Informations clés
0%
Ratio d'endettement
€0
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | €17.30b |
Fonds propres | €19.07b |
Total du passif | €3.17b |
Total des actifs | €22.24b |
Mises à jour récentes de la santé financière
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05Recent updates
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19Analyse de la situation financière
Passif à court terme: Les actifs à court terme de BNTX ( €18.3B ) dépassent ses passifs à court terme ( €2.4B ).
Passif à long terme: Les actifs à court terme de BNTX ( €18.3B ) dépassent ses passifs à long terme ( €739.7M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BNTX est sans dette.
Réduire la dette: BNTX n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 3%.
Couverture de la dette: BNTX n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.
Couverture des intérêts: BNTX n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.